As per the terms of the settlement, Lupin will be licensed under the relevant desloratadine patents, and free to commercially launch its generic desloratadine product, on July 1, 2012, or earlier in certain circumstances.
Kamal Sharma, managing director of Lupin, said: “The settlement with Schering-Plough leaves us strategically poised to further strengthen, consolidate and grow our market position in the US markets.
“Furthermore, the settlement, recent product approvals and growth in filings across markets are a testament to our increased strengths and focus on R&D and the quality of our intellectual property – a testimony to Lupin’s larger goal of developing and delivering quality, cost-effective drugs for everybody.”